Navigation Links
American Fertility Association Calls for Expanded Research to Advance New Technology to Screen Embryos for Genetic Abnormalities
Date:10/18/2007

d by researchers at Reproductive Medicine Associates of New Jersey (RMANJ).

"Accurate and rapid identification of chromosomally-abnormal (aneuploid) embryos within hours after embryo biopsy will provide physicians with the ability to select embryos for transfer to the uterus based on a far more complete and accurate picture of their genetic health than has ever been possible," said Nathan Treff, Ph.D., researcher at RMANJ and principal investigator and lead author of the study. "This could, in turn, allow us to reduce the number of embryos implanted while increasing the chances that couples treated with IVF will have a healthy baby."

Currently, the most commonly used technology for chromosomal analysis of embryos (sometimes termed preimplantation genetic diagnosis or PGD), is florescent in situ hybridization (FISH). This technique assesses fewer than half of the 23 chromosome pairs found in the human karyotype and has a suboptimal error rate. This makes it possible for many genetic abnormalities to go undetected. Prior technologies that have attempted to analyze all 23 chromosome pairs have not been useful because of the length of time required to provide accurate results.

"To improve safety and success in IVF, we must improve our ability to screen embryos. That's why this research is so important and why we must support every effort to make this new technology available to patients," Ms. Madsen added.

In this new process, a single cell is removed from an embryo and the genetic code for that cell is copied up to a million times. Once amplified, approximately 250,000 different areas of the DNA, called single nucleotide polymorphisms (SNPs, or "snips"), are individually examined. This process makes it possible to identify any deviations from the normal genetic copy. This information can, in turn, help doctors to identify embryos that offer the highest chances of successful implantation, healthy pregnancy, and a healthy baby.

About the AFA
'/>"/>

SOURCE American Fertility Association
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
6. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
7. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
8. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
9. Bentley Reports Positive Results with Nasulin Intranasal Insulin Spray at the American Diabetes Association Meeting
10. Elixir Pharmaceuticals Announces Clinical Data at American Diabetes Association Conference Highlighting Ability of Glufast to Maintain Glycemic Control in Patients with Type 2 Diabetes
11. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 2Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 2Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 3Sysmex Supports Illinois Chapter Leukemia and Lymphoma Society 52505 1Sysmex Supports Illinois Chapter Leukemia and Lymphoma Society 52505 2President Obamas Health Care Plan 3A Too Big Too Expensive Too Rushed 52500 1President Obamas Health Care Plan 3A Too Big Too Expensive Too Rushed 52500 2President Obamas Health Care Plan 3A Too Big Too Expensive Too Rushed 52500 3St Johns Hospital Acquires Latest Technology in Robotic Assisted Surgery 13163 1St Johns Hospital Acquires Latest Technology in Robotic Assisted Surgery 13163 2